Apellis Pharmaceuticals and Sobi secured FDA approval to expand the label of Empaveli, targeting two rare kidney diseases affecting around 5,000 patients in the U.S. This regulatory expansion opens a new market segment for the complement inhibitor, potentially improving treatment options for patients afflicted with these conditions. The approval underscores ongoing progress in complement-targeted therapies for rare renal disorders.